[PRC BOARD OF PHARMACY RESOLUTION NO. 07, SERIES 2004, January 29, 2004]

PROMULGATION OF GUIDELINES FOR THE REGISTRATION OF MEDICAL REPRESENTATIVES/DETAILMEN WITH THE BOARD OF PHARMACY

WHEREAS, Sec. 12 of R.A. No. 5921 provides as follows:

> "Section 12. Detailmen Requirements, Qualifications and Fees. - Any person who shall be employed as detailman by any pharmaceutical or drug laboratory or other manufacturers of medical, dental pharmaceutical, biological and veterinary products and by distributors, dealers or wholesalers of said products, doing business directly or indirectly in the Philippines, shall be required, at the beginning of each year, to register with the Board of Pharmacy that he is employed as such.
>
> a. An applicant for registration shall be, preferably, a graduate of a college of pharmacy.
>
> There shall be an initial fee of 150.00 pesos upon registration and thereafter fifteen pesos shall be charged annually for renewal. Upon payment of said fees, the proper credential shall be issued to the applicant. (These particular provision is now superceded by PRC Res. No. 98- 560 Series of 1998, which prescribed a fee of P200. And P100 for original registration and annual license fee for detailmen, respectively).
>
> b. It shall be incumbent upon the drug establishment referred to in this section to require that detailmen employed or to be employed by them possess the necessary credentials issued by the Board of Pharmacy as provided for herein.

For purposes of this section, a detailman is one who represents any duly authorized manufacturer, dealer, distributor, representative or wholesaler of drugs pharmaceuticals, biologic products and devices, whose primary duty is to introduce or reacquaint a product or products prepared, distributed or made by said manufacturer, dealer, distributor, representative or wholesaler to the physician, dentist, pharmacist, veterinarian or any other qualified person and which form part of their program for promotion by describing its use, composition, action, dosage, administration, contraindication, advantages and other salient information relative to said products."

WHEREAS, on February 1, 1977, the Board issued Memorandum Circular (MC) to